Aeglea BioTherapeutics Shares Plummet Following Refusal To File Letter From FDA
Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE) announced the U.S. Food and Drug Administration (FDA) has refused to accept the company’s Biologics License Application (BLA) with a Refusal to File (RTF) letter.
Benzinga ·
Benzinga
